Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 – October 2, 2024, in Washington, D.C.
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
